Francis deSouza, Illumina CEO (Photographer: Kyle Grillot/Bloomberg via Getty Images)
As Illumina disappoints Wall Street, competitors make their case at JPM
Last September, Illumina pledged to decipher a person’s genetic code for as little as $200 with its new sequencing machines, part of a wider push to make genetic testing a routine part of check-ups.
At the JP Morgan Healthcare Conference on Wednesday, competitor Element Biosciences said its technology could also sequence a genome for $200 – and potentially with machines that cost less.
“Our goal is to democratize sequencing by driving down costs,” said Element CEO Molly He.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters